Skip to main content
  • Original Article
  • Open access
  • Published:

Proton pump inhibitors as treatment of laryngeal disorders among patients with gastroesophageal reflux disease: a single-arm (pre and post) quasi-experimental study



Laryngopharyngeal reflux is a silent cause of laryngeal disorders which was documented in the last decade by many studies. This study aimed to evaluate the prevalence of laryngeal reflux in GERD cases and to evaluate the effect of GERD treatment on these laryngeal disorders.


In this single-arm (pre and post) quasi-experimental study, eighty patients with GERD were examined for laryngeal disorders by rigid laryngoscopy and assessed by the Reflux Finding Score (RFS). Complaints of patients were evaluated using the 9-item Reflux Symptom Index (RSI) questionnaire. Patients received medical treatment of GERD in the form of proton pump inhibitors (PPIs) only, and they were reassessed after 3 months for improvement in their symptoms and signs using RSI and RFS systems to compare patient complaints and findings in the laryngeal endoscopy pre- and post-treatment.


Among 80 confirmed GERD cases, 70 (87.5%) suffered from laryngeal disorders. Throat clearing and postnasal drip were the most prevalent symptoms, and ventricular obliteration and erythema, vocal fold and diffuse laryngeal edema, and posterior commissure hypertrophy were the most detected signs. Significant improvement in both symptoms and signs after 3 months of PPI therapy was clearly observed. The resistance rate among our studied patients was reported to be 22.4%.


GERD can be considered as an inducer or cause of laryngeal disorders, with a significant direct proportional relationship between the severity of GERD and both the RSI and RFS. PPI greatly improves laryngeal disorders among GERD patients with a high response rate (77.6%).


Gastric reflux disease is defined as a GIT motility disorder that results from the reflux of gastric juice into the esophagus or oral cavity, causing symptoms or complications. Gastric juice reflux can affect organs other than the esophagus as far as they ascend, so GERD can be divided into extraesophageal reflux, atypical reflux, laryngopharyngeal reflux (LPR), and reflux laryngitis. Laryngopharyngeal reflux disease (LPRD) is caused by the backflow of stomach contents and/or gastric acid into the laryngopharynx [1].

Extraesophageal manifestations of GERD recently started to have an important role in causing respiratory tract diseases. Clinically, LPR is known as “silent reflux” with rarely associated gastric symptoms, and treatment is usually delayed because of inadequate diagnostic and therapeutical protocols. Laryngeal symptoms are the most common complaints as the first organ to be exposed to the refluxed gastric juice, so patients are usually treated by otolaryngologists. Otolaryngologists developed Reflux Symptom Index (RSI), as a diagnostic tool, according to the importance of certain disease symptoms which uses a 0–5 rating scale (with 0 = no problem and 5 = severe) [2].

Laryngopharyngeal reflux (LPR) is characterized by dysphonia, globus pharyngeus (lump sensation in the throat), hoarseness, recurrent throat clearing, and chronic cough. LPR represents about 10% of all ENT clinic patients and half of voice complaint patients. But, due to the lack of a good diagnostic test, the prevalence of LPR may be overestimated. A meta-analysis reviewed that 10 to 60% of normal subjects demonstrated reflux from pH probe reading reporting [3].

Laryngoscopy is used to discover laryngeal pathological changes described as hyperemia or erythema of the vocal folds and laryngeal edges, edema, granulation, presence of dense endolaryngeal secretion ventricular obliteration, and hypertrophy of the posterior commissure [4]. The Reflux Finding Score (RFS) based on these laryngoscopic signs is used by some studies to evaluate the effect of LPR on the larynx.

Jamie Koufman published one of the first studies in 1991 investigating the estimated LPR incidence in outpatients presenting to otolaryngology clinics with extraesophageal manifestations of GERD. Patients with otolaryngologic disorders having suspected GERD were evaluated, and after 6 months of treatment with antireflux therapy, 85% of patients resolved [5].

Connor et al. aimed to determine the prevalence of extraesophageal reflux disease (EERD) and the effect on health-related quality of life in adults within a large community-based sample. They found that about 66% of subjects reported either laryngeal symptoms or GERD and 26% reported both laryngeal symptoms and GERD (reflects symptoms commonly reported for LPR) and 39% of patients had medicine for heartburn. Forty-four percent of patients with both laryngeal disorders and GERD had breathing difficulties, and 38% had voice changes. Significant reductions in voice-related quality of life, digestive health, and general health were found in patients with both laryngeal disorders and GERD, in comparison to patients manifesting each symptom alone, or in asymptomatic patients [6].

A study by Habermann et al. aimed to evaluate if patients over a period of 20 months with abnormal RSI and Reflux Finding Score (RFS) benefit from proton pump inhibitor (PPI) therapy. The estimated treatment effect by doctors and patients was 50% excellent. Patients with positive results of RSI and RFS had excellent improvements after 8–12 weeks of PPI treatment [7].

A study by Chen et al. aimed to assess the prevalence of laryngopharyngeal reflux disease (LPRD) in the Fuzhou region in China on subjects aged from 10 to 70 years. Subjects with a total RSI score of more than 13 were defined as having LPRD. The author found that the prevalence of LPRD was 5.0% and the prevalence in subjects of 30–39 years old was significantly more than that in subjects of 10–19 years old and in men was higher than in women [8].

Gao et al. found that there was a significant difference in the RFS cutoff between the genders. For male subjects, the author recommends a cutoff of 9.0 for diagnosing LPRD, and for female subjects, he recommends a cutoff of 6.0 [9].

Finally, a prospective study evaluated the prevalence of laryngeal reflux symptoms in cases of GERD in 200 Egyptian patients by applying RFS and RSI. The patients were divided into two groups, patients with and without laryngeal reflux symptoms. The author reported that for group I, GERD was found in all 100% of patients, and all patients had symptoms and signs of laryngeal reflux, and for group II, 92% of patients were found to be free of laryngeal reflux signs and 8% of patients were found to have signs of laryngeal reflux (silent laryngeal reflux) [10].

The aim of this study was to study the prevalence of laryngeal disorders among GERD patients and to determine the effect of GERD treatment on these laryngeal disorders without any treatment to laryngeal disorders.



This study is considered a single-arm (pre-post) quasi-experimental study and was conducted between the otorhinolaryngology department and gastroenterology department, Faculty of Medicine, Assiut University Hospital, Egypt, from January 2020 to October 2021 on patients diagnosed to have GERD by either gastroscopy or 24-h PH-esophageal monitoring at GIT and tropical medicine department. All patients diagnosed in the Gastroenterology Department to have gastroesophageal reflux were examined in the ENT Department by laryngoscopy during the study period.

Using G*Power 3 software, a calculated minimum sample of 80 patients were needed to detect an effect size of 0.3 in the mean of RFS and RSI on two repeated occasions, with an error probability of 0.05 and 80% power on a two-tailed test.

Inclusion criteria are as follows:

  1. 1.

    Sex: male and females

  2. 2.

    Age: adult persons from 18 years old up to 60 years old

  3. 3.

    Diagnosed to have gastric reflux before the start of treatment

Exclusion criteria are as follows:

  1. 1.

    Patients below 18 years

  2. 2.

    Voice abusers as singers, teachers, and readers

  3. 3.

    Patients refused to participate in our study

  4. 4.

    Pregnant females


Eligible patients were subjected to the following preliminary evaluation

  1. A.

    Name, age, sex, residence, occupation, marital status, and special habits.

  2. B.

    Full history to assess the general condition of the patient.

  3. C.

    Complaints of patients who were diagnosed with GERD were evaluated with the 9-item Reflux Symptom Index (RSI) questionnaire, including symptoms of hoarseness, postnasal discharge, throat clearing, difficulty of swallowing, cough after eating, breathing difficulties, annoying cough, globus sensation, and heartburn. Patients rated their severity from 0 to 5 as 0: no and 5: severe (difficult to tolerate, preventing daily activities) with RSI greater than or equal to 13 being clinically significant and indicative of significant reflux disease [2].

  4. D.

    The laryngeal findings were evaluated by using a rigid laryngoscope at the outpatient clinic. The findings were evaluated by a Reflux Finding Score (RFS) based on 8 laryngoscopic findings (subglottic edema, diffuse laryngeal edema, ventricular edema, vocal cord edema, erythema, thick endolaryngeal mucus, hypertrophy of the posterior commissure and granuloma, or granulation tissue) which scored ranging from 0 (best) to 26 (worst); scores greater than or equal 7 were positive [11].

  5. E.

    Strategy that was put for treatment only for GERD:

    • Proton pump inhibitors in the form of omeprazole 40mg once daily 1h before breakfast without any treatment to laryngeal symptoms and follow-up after 3 months

    • Lifestyle modifications as avoiding reflux-enhancing foods, using high pillows while sleeping, and taking dinner 4 h before sleep were made.

    • Reflux Symptom Index and laryngeal findings as Reflux Finding Score were evaluated again with the same methods after treatment.

    • Data before and after treatment were compared statistically.

Operational design

The researcher introduced himself to the patients included in this study and illustrated to them the goal of the study. All participants received comprehensive information regarding the objectives and the expected benefits of the study. All ethical considerations were taken throughout the whole work.

Statistical analysis

All statistical calculations were done using SPSS version 22. Data were expressed as mean ± standard deviation, or median and range when not normally distributed, number of cases and percentages when appropriate. A comparison of quantitative paired variables was done using a paired sample t test for normally distributed data. The chi-square (χ2) test was performed for comparing categorical data. An exact test was used instead when the expected frequency is less than 5. The P-value is always 2-tailed set significant if ≤ 0.05 level.


A total of 80 patients who presented to our outpatient clinic after being referred from the Gastroenterology Department diagnosed with GERD were included in our study. The mean age of enrolled patients was 37.56 ± 9.51 years with a range between 18 and 60 years. Out of 80 studied GERD cases, 38 (47.5%) were males and 42 (52.5%) were females (Table 1). Seventy (87.5%) patients had laryngeal disorders out of the eighty patients, while 10 (12.5%) patients had no laryngeal disorders as the Reflux Finding Score by laryngoscopic examination was below 7.

Table 1 Demographic distribution of patients

Our study included 70 patients who had laryngeal disorders, 3 of them were missed in the follow-up, so sixty-seven patients were included in our study. All patients at baseline had throat clearing and postnasal drip. Other frequent symptoms at baseline were coughing after eating or lying down (98.5%), sensation of something sticking in the throat (97.0%), and heartburn, chest pain, indigestion, or stomach acid coming up (83.6%). At baseline, all patients had reflux symptoms more than 13 while after therapy 52 (77.6%) patients had an index < 13 and 15 (22.4%) patients had an index ≥ 13 (Table 2).

Table 2 Comparison between laryngeal symptoms among studied patients and the mean of each symptom in RSI score before and after treatment

During follow-up, after 3 months of gastric reflux treatment, there was a significant improvement in all laryngopharyngeal reflux symptoms according to the number of patients except hoarseness and breathing difficulty and to the severity of all laryngopharyngeal reflux symptoms except breathing difficulty according to the Reflux Symptom Index score (Table 2).

At baseline, all studied participants suffered from ventricular obliteration, erythema or hyperemia, vocal fold edema, diffuse laryngeal edema, and posterior commissure hypertrophy. 61.2% suffered from subglottic edema, 44.8% suffered from granuloma or granulation, and 73.1% suffered from thick endolaryngeal mucus (Table 3). During follow-up, there was a significant improvement in the number of patients having subglottic edema, ventricular obliteration, granuloma, or granulations and thick endolaryngeal mucus (P<0.001 for all) but not for ventricular obliteration, erythema or hyperemia, vocal fold edema, diffuse laryngeal edema, and posterior commissure hypertrophy as 100% of the studied participants still suffered from it. There was a significant improvement in the severity of all laryngeal signs according to the Reflux Finding Score (Table 3) and in reflux findings during follow-up. At baseline, all patients (100.0%) had a Reflux Finding Score > 7 while during follow-up the majority (77.6%) of patients had a Reflux Finding Score < 7.

Table 3 Reflux finding scores among studied patients and reflux finding score severity at baseline and follow-up

It was found that gastroesophageal reflux therapy was effective in 52 (77.6%) patients while 15 (22.4%) patients had no improvement as the RSI was still more than 13 and RFS more than 7.

There was a positive correlation between RSI and RFS as the greater the RSI, the greater the RFS (Fig. 1).

Fig. 1
figure 1

Scatter plot graph showing the correlation between Reflux Finding Score and Reflux Symptom Index


The retrograde movement of stomach contents into the esophagus, larynx, and pharynx, known as laryngopharyngeal reflux (LPR), is thought to be an extraesophageal symptom of gastroesophageal reflux disease (GERD), causing tissue damage in these regions and symptomatizing as odynophagia, pharyngeal globus, throat clearing, dysphonia, dry cough, and laryngospasm crisis [12]. It became to be significant and increasingly common disease seen by an otolaryngologist, with an estimated range from 18 to 80% [13].

The mean age of the studied participants was 37.56 ± 9.51 years and ranged from 18 up to 60 years. In agreement with our study, Gaber et al. [10], Patigaroo et al. [14], Mosli et al. [15] found that the mean age of the LPR cases was 38, 40.1 ± 11.8 and 43 ±16 years, respectively.

It is well known that advancing age has been inconsistently associated with an increased risk for GERD symptoms. In a meta-analysis, the summary odds ratio for 50 years or more versus less than 50 years of age was 1.32 [16]. In our study, we only included GERD cases who attended our clinic before starting any treatment; this explains the younger age at the time of GERD diagnosis among our studied participants.

No sex predilection was found in our study among studied GERD cases, as 38 (47.5%) were males and 42 (52.5%) were females out of 80 studied GERD cases. In line with our research, Gaber et al. reported that 50% of the studied cases were males with a male to female ratio of 1:1 [10]. Also, in line with our study, GERD symptoms are not associated with sex in North America or Europe, but in South America and the Middle East, women are almost 40% more likely to report GERD symptoms than males [16].

The manifestations of GERD were divided into esophageal and extraesophageal disorders, and the association between laryngopharyngeal reflux disease (LPR) and GERD has been established according to the Montreal Consensus Conference [17]. In this current study, in order to determine the prevalence of laryngeal reflux in GERD cases, all studied participants were evaluated by laryngoscopic examination using the Reflux Finding Score (RFS). RFS is an 8-item clinical severity scale that depends on the fiberoptic laryngoscopy findings. The scale ranges from 0 which means no abnormal findings to 26 which is the worst possible score.

Also, complaints of GERD patients were evaluated with Reflux Symptom Index (RSI), first described by Belafsky et al., as a self-administered and validated 9-item scoring system designed to assess the symptoms related to LPR (throat clearing, excess throat mucus or postnasal drip, hoarseness, breathing difficulties, dysphagia, globus pharyngeus, coughing after eating or lying down, troublesome or annoying cough, and heartburn) [2]. An RSI score quantifies the severity of LPR symptoms on a scale of 0–5, with a total score of 45 indicating the most severe form. RSI levels above 13 are considered abnormal and suggest LPR, which is used as the diagnostic cutoff point. Farahat et al. developed an Arabic version of the RSI which was used in the current study [18].

In this study, 80 patients with confirmed GERD were examined and 70 patients (87.5%) of them were diagnosed with LPR. In line with our study, many previous studies reported a strong correlation between the two conditions (laryngopharyngeal disorders and GERD). Tauber et al. reported 69% of patients with GERD had laryngitis confirmed by inter-arytenoid edema and erythema diagnosed by laryngoscopic examination [19]. Also, a study by Vardar et al. had similar results as LPR was reported in 70% of patients diagnosed with GERD [20]; recently, Mosli et al. reported that 71% of confirmed GERD patients had LPR [15]; and lastly, Silva et al. reported that 82.8% of confirmed GERD cases had LP [12].

According to RFS, all studied participants at the baseline examination were suffering from ventricular obliteration, erythema or hyperemia, diffuse laryngeal edema, vocal fold edema, and posterior commissure hypertrophy. 61.2% suffered from subglottic edema, 44.8% suffered from granuloma or granulation, and 73.1% suffered from thick mucus endolaryngealy, and the mean RFS was about 14.12 ± 2.87 and ranged from 1 up to 21.

Other studies have also found that the most common laryngeal finding “as assessed by RFS” was found to be erythema/hyperemia like studies of Book et al., Mesallam et al., Karkos et al., Toros et al., Patigaroo et al., and Osman et al. [13, 14, 21,22,23,24]. Also, other authors have noted that the most common laryngoscopic signs are posterior commissure hypertrophy as by Belafsky et al. and partial ventricular obliteration as by Tezer et al. [11, 25].

After 3 months of gastric reflux treatment with PPIs, significant improvement was noticed in all abovementioned findings (P<0.001 for all) except for ventricular obliteration, erythema or hyperemia, vocal fold edema, diffuse laryngeal edema, and posterior commissure hypertrophy as 100% of the studied participants still suffered from it. However, there was a significant decrease in the mean values of the used RFS for all these items from before to after treatment (P<0.001), and the mean RFS was significantly decreased from 14.12 ± 2.87 to 7.49 ± 4.80, P<0.001.

Our study showed similar results to other studies done for the response of RFS to PPI like studies of Belafsky et al., who reported that the mean of RFS at entry was 11.5 (± 5.2 SD) and improved to 9.3 (± 4.7 SD) at 2 months, 7.3 (± 5.5 SD) at 4 months, and 6.1 (± 5.2 SD) at 6 months of treatment with PPIs [11]. Bilgen et al. reported that the RFS before the start of the therapy was 14.8±3.8 and improved significantly to 7.7±3.8 at the second month, to 4.5±2.3 at the fourth month, and to 1.4±0.9 at the sixth month of treatment with proton pump inhibitors [26]. Also, our study was supported by the recent study of Silva et al., who reported that the RFS assessment showed a reduction in the values when compared with the pre- and post-treatment with 90 days with PPI [12].

According to RSI, at baseline, the most common symptom in the study was found to be clearing throat and postnasal drip in 100% of the study population, followed by coughing after eating or lying down documented in 98.5%, sensation of something sticking in throat 97.0%, then chest pain, heartburn, stomach acid coming up, or indigestion documented in 83.6%; the mean RSI was 19.84 ± 4.96 and ranged from 14 up to 32.

In line with our results, Toros et al. found frequent clearing of the throat as the most common symptom [24], while some studies have found other most common symptoms of LPR like the study of Patigaroo et al. who found the most common symptom to be globus sensation in 74% of patients followed by the frequent clearing of the throat in 64% of patients and annoying coughing in 56% of the study population and the least common symptom was breathing difficulties [14]. Studies of Issing et al., Mesallam et al., Karkos et al., and Osman et al. also found that the most common symptom like our study was globus pharyngeus [13, 22, 23, 27].

After 3 months of gastric reflux treatment with PPIs, we observed significant improvement in all laryngopharyngeal reflux symptoms “as assessed by RSI” except hoarseness of voice and breathing difficulty. However, there was a significant decrease in the mean values of the used RSI for hoarseness of voice, but not for breathing difficulty, which was still a problem facing our patients, from before to after treatment (P<0.001), and the mean RSI was significantly decreased from 19.84 ± 4.96 to 11.94 ± 10.61, P<0.001.

Similar results were obtained in other studies like the study by Belafsky et al. who reported that the mean RSI of LPR patients improved from 21.2 ± 10.7 to 12.8 ± 10.0 after 6 months of treatment with PPI [2]. Also, the study of Patigaroo et al. reported that the mean of RSI before treatment for all patients was 24.75, and after 8 weeks of treatment with PPI, it decreased to 13.5 and after 16 weeks dropped to 13.25 [14]. Osman et al. reported reflux symptoms markedly improved at the end of 2 months and 6 months of PPI therapy with significant [13]. Also, our study was supported by the recent study of Silva et al. who reported that the RSI assessment showed a decrease in the values when compared to the pre- and post-treatment values with PPI for 3 months (p <0.001) [12].

We reported a 22.4% resistance rate among our studied participants. Some studied patients still have persistent signs, as 100.0% still have erythema or hyperemia, vocal fold edema, diffuse laryngeal edema, and posterior commissure hypertrophy; 22.4% still have ventricular obliteration; 19.4% still have subglottic edema; 17.9% still have thick mucus endolaryngealy; and three cases (4.5%) still have granuloma. Persistent symptoms such as throat cleaning in 86.6%, 82.1% still suffering from hoarseness of voice, 67.1% from postnasal drip, 67.2% from globus pharyngeus, 61.2% from heartburn, 53.7% from difficult swallowing, 52.2% from coughing post-prandial or on lying down or annoying cough, and 49.3% still suffering from breathing difficulties were still detected 3 months post-PPI therapy.

Osman et al.’s study detected the persistence of some of the presenting signs after still 6 months post-therapy: partial ventricular obliteration was still detected in 8 (13.1%) of included patients, mild vocal fold edema in 10 (16.4%) of patients, mild laryngeal edema in 7 (11.5%) of patients, and granuloma in 6 (9.8%) of them [13].

On the other hand, other studies show higher response rates like studies of Jaspersen et al. and Patigaroo et al. which demonstrated completely (100%) symptom-free patients after treatment with 40 mg omeprazole per day, and Kamel et al. found the response rate was 92% [14, 28, 29].

The difference between this study and the previously mentioned studies leads us to question the duration of treatment, which in the present study led to a discrete reduction in the overall sum of the RFS from 14.12 to 7.49 and RSI from 19.84 to 11.94. Perhaps a longer follow-up time could change the profile of these scores since our follow-up was of only 3 months. Also, it is well known that unlike GERD, response to PPI in patients with LPR has been described to be highly variable. This may be due to that LPR require prolonged and more aggressive therapy, which may last for several months, than GERD [30]. This finding was confirmed by Belafsky et al. in 2001 and 2002 who found a more improvement in the scores of individuals treated with PPIs for 6 months, double the time used in our study [2, 11].

One of the limitations of our study was the small sample size, so larger prospective studies are needed to confirm the role of PPI in controlling the laryngeal disorders associated with GERD disease and evaluate its long-term side effects. Another limitation of our study may be the subjectivity of RFS, as these signs can be present in up to 86% of asymptomatic subjects, because both the interobserver and interobserver reproducibility of laryngeal signs due to LPR is poor, which may lead to overdiagnosis of laryngopharyngeal reflux; evaluation of the patients by two examiners is needed. There is a vital need for the implementation of RSI and RFS in daily use to decrease time consumption and expensive examinations for patients and to help in early diagnosis of LPR with a subsequent decrease in serious complications such as laryngeal granuloma, subglottic stenosis, and laryngeal cancer.


From this study, it was concluded that laryngopharyngeal reflux disease (LPRD) is becoming a commonly diagnosed condition among pharyngeal and voice disorders and the diagnosis depends on full history and clinical examination followed by laryngeal endoscopy. A large percentage (87.5%) of GERD patients had laryngeal disorders. The main complaint was throat clearing and postnasal drip, i.e., 100% each, while ventricular obliteration, erythema or hyperemia, vocal fold edema, diffuse laryngeal edema, and posterior commissure hypertrophy were the most obvious signs, i.e., 100% each. There was a significant direct proportional relationship between the severity of GERD and both the RSI and RFS. PPI greatly improves laryngeal disorders among GERD patients with a high response rate (77.6%).

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.


  1. Chiba T (2017) Laryngopharyngeal reflux disease (LPRD)–Review article. Med Res Arch 5(2)

  2. Belafsky PC, Postma GN, Koufman JA (2002) Validity and reliability of the reflux symptom index (RSI). J Voice. 16(2):274–277

    Article  Google Scholar 

  3. Patel DA, Blanco M, Vaezi MF (2018) Laryngopharyngeal reflux and functional laryngeal disorder: perspective and common practice of the general gastroenterologist. Gastroenterol Hepatol 14(9):512

    Google Scholar 

  4. Campagnolo AM, Priston J, Thoen RH, Medeiros T, Assunção AR (2014) Laryngopharyngeal reflux: diagnosis, treatment, and latest research. Int Arch Otorhinolaryngol 18:184–191

    Google Scholar 

  5. Koufman JA (1991) The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope. 101:1–78

    Article  CAS  Google Scholar 

  6. Connor NP, Palazzi-Churas KL, Cohen SB, Leverson GE, Bless DM (2007) Symptoms of extraesophageal reflux in a community-dwelling sample. J Voice. 21(2):189–202

    Article  Google Scholar 

  7. Habermann W, Schmid C, Neumann K, DeVaney T, Hammer HF (2012) Reflux symptom index and reflux finding score in otolaryngologic practice. J Voice. 26(3):e123–e127

    Article  Google Scholar 

  8. Chen XM, Li Y, Guo WL, Wang WT, Lu M (2016) Prevalence of laryngopharyngeal reflux disease in Fuzhou region of China. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 51(12):909–913

    CAS  Google Scholar 

  9. Gao CK, Li YF, Wang L, Han XY, Wu T, Zeng FF, Li XP (2018) Different cutoffs of the reflux finding score for diagnosing laryngopharyngeal reflux disease should be used for different genders. Acta Oto Laryngol. 138(9):848–854

    Article  Google Scholar 

  10. Gaber S, Ebraюm SA, Menaem MA, Mohamed SF (2019) Laryngeal disorders in Egyptian patients with gastroesophageal reflux disease. Med J Cairo Univ 87(September):3519–3524

    Article  Google Scholar 

  11. Belafsky PC, Postma GN, Koufman JA (2001) The validity and reliability of the reflux finding score (RFS). Laryngoscope. 111(8):1313–1317

    Article  CAS  Google Scholar 

  12. Silva ÁS, Duprat AC, Machado SR, Melo DN, Ribeiro DK (2021) Evaluation of the reflux symptom index and the endolaryngeal findings scale after treatment in individuals with laryngopharyngeal reflux. Int Arch Otorhinolaryngol 25:115–122

    Article  Google Scholar 

  13. Osman HA, Abd Elrhman NH, Shafy MA (2019) The efficacy of PPI in the treatment of laryngopharyngeal reflux. J Gastroenterol Hepatol Res 8(1):2800–2806

    Article  CAS  Google Scholar 

  14. Patigaroo SA, Hashmi SF, Hasan SA, Ajmal MR, Mehfooz N (2011) Clinical manifestations and role of proton pump inhibitors in the management of laryngopharyngeal reflux. Indian J Otolaryngol Head Neck Surg 63(2):182–189

    Article  Google Scholar 

  15. Mosli M, Alkhathlan B, Abumohssin A, Merdad M, Alherabi A, Marglani O, Jawa H, Alkhatib T, Marzouki HZ (2018) Prevalence and clinical predictors of LPR among patients diagnosed with GERD according to the reflux symptom index questionnaire. Saudi J Gastroenterol 24(4):236

    Article  Google Scholar 

  16. Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC (2018) Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 67(3):430–440

    Article  Google Scholar 

  17. Vakil N, Van Zanten SV, Kahrilas P, Dent J, Jones R (2006) The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Official J Am College Gastroenterol 101(8):1900–1920

    Article  Google Scholar 

  18. Farahat M, Malki KH, Mesallam TA (2012) Development of the Arabic version of reflux symptom index. J Voice. 26(6):814–e15

    Article  Google Scholar 

  19. Tauber S, Gross M, Issing WJ (2002) Association of laryngopharyngeal symptoms with gastroesophageal reflux disease. Laryngoscope. 112(5):879–886

    Article  Google Scholar 

  20. Vardar R, Varis A, Bayrakci B, Akyildiz S, Kirazli T, Bor S (2012) Relationship between history, laryngoscopy and esophagogastroduodenoscopy for diagnosis of laryngopharyngeal reflux in patients with typical GERD. Eur Arch Oto Rhino Laryngol 269(1):187–191

    Article  Google Scholar 

  21. Book DT, Rhee JS, Toohill RJ, Smith TL (2002) Perspectives in laryngopharyngeal reflux: an international survey. Laryngoscope. 112(8):1399–1406

    Article  Google Scholar 

  22. Mesallam TA, Stemple JC, Sobeih TM, Elluru RG (2007) Reflux symptom index versus reflux finding score. Ann Otol Rhinol Laryngol 116(6):436–440

    Article  Google Scholar 

  23. Karkos PD, Yates PD, Carding PN, Wilson JA (2007) Is laryngopharyngeal reflux related to functional dysphonia? Ann Otol Rhinol Laryngol. 116(1):24–29

    Article  Google Scholar 

  24. Toros SZ, Toros AB, Yüksel OD, Ozel L, Akkaynak C, Naiboglu B (2009) Association of laryngopharyngeal manifestations and gatroesophageal reflux. Eur Arch Oto Rhino Laryngol 266(3):403–409

    Article  Google Scholar 

  25. Sabri Tezer M, Cem Kockar M, Koçkar O, Celik A (2006) Laryngopharyngeal reflux finding scores correlate with gastroesophageal reflux disease and Helicobacter pylori expression. Acta Oto Laryngol 126(9):958–961

    Article  Google Scholar 

  26. Bilgen C, Ögüt F, Kesimli-Dinç H, Kirazli T, Bor S (2003) The comparison of an empiric proton pump inhibitor trial vs 24-hour double-probe pH monitoring in laryngopharyngeal reflux. J Laryngol Otol 117(5):386–390

    Article  Google Scholar 

  27. Issing WJ, Karkos PD, Perreas K, Folwaczny C, Reichel O (2004) Dual-probe 24-hour ambulatory pH monitoring for diagnosis of laryngopharyngeal reflux. J Laryngol Otol 118(11):845–848

    Article  CAS  Google Scholar 

  28. Jaspersen D, Weber R, Hammar CH, Draf W (1996) Effect of omeprazole on the course of associated esophagitis and laryngitis. J Gastroenterol 31(6):765–767

    Article  CAS  Google Scholar 

  29. Kamel PL, Hanson D, Kahrilas PJ (1994) Omeprazole for the treatment of posterior laryngitis. Am J Med 96(4):321–326

    Article  CAS  Google Scholar 

  30. Postma GN, Halum SL (2006) Laryngeal and pharyngeal complications of gastroesophageal reflux disease. GI Motility online.

Download references


Not applicable.


No fund was received for this study.

Author information

Authors and Affiliations



MAR: Conception and design, acquisition of data, analysis and interpretation of data and critical revision of the submitted protocol for important intellectual content. SSS: Data collection. EEM: Examination of patients at gastroenterology department and diagnosis and treatment of GERD. HAMA: Patient examination in phoniatric unit. MMR: Analysis and interpretation of data and supervision. The author(s) read and approved the final manuscript.

Corresponding author

Correspondence to Mahmoud Ali Ragaee.

Ethics declarations

Ethics approval and consent to participate

The protocol of the study had been approved by Assiut Medical Ethical Review Board under IRB no:17101130 clinical trials approval (NCT04231344). All studied patients who participate in this study had received their medical care free of charge. For patients who refused to participate in the study, it did not affect the quality of care they had received. An informed written consent from all participants was taken and confidentiality of information was ensured all through the study.

Consent for publication

Not applicable.

Competing interests

No conflict of interest exists.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ragaee, M.A., Sedik, S.S., Ahmed, H.A.E.R.M. et al. Proton pump inhibitors as treatment of laryngeal disorders among patients with gastroesophageal reflux disease: a single-arm (pre and post) quasi-experimental study. Egypt J Otolaryngol 39, 10 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: